Production (Stage)
Kyverna Therapeutics, Inc.
KYTX
$3.39
$0.4515.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 37.43M | 33.48M | 29.19M | 27.32M | 22.48M |
| Gross Profit | -37.43M | -33.48M | -29.19M | -27.32M | -22.48M |
| SG&A Expenses | 9.98M | 10.36M | 7.88M | 6.11M | 5.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.41M | 43.84M | 37.07M | 33.44M | 28.26M |
| Operating Income | -47.41M | -43.84M | -37.07M | -33.44M | -28.26M |
| Income Before Tax | -44.64M | -37.49M | -34.49M | -28.80M | -26.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.64M | -37.49M | -34.49M | -28.80M | -26.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.64M | -37.49M | -34.49M | -28.80M | -26.69M |
| EBIT | -47.41M | -43.84M | -37.07M | -33.44M | -28.26M |
| EBITDA | -46.91M | -43.52M | -36.75M | -33.14M | -27.78M |
| EPS Basic | -1.03 | -0.87 | -0.80 | -0.67 | -1.12 |
| Normalized Basic EPS | -0.65 | -0.58 | -0.47 | -0.42 | -0.67 |
| EPS Diluted | -1.03 | -0.87 | -0.80 | -0.67 | -1.12 |
| Normalized Diluted EPS | -0.65 | -0.58 | -0.47 | -0.42 | -0.67 |
| Average Basic Shares Outstanding | 43.22M | 43.23M | 43.16M | 43.13M | 23.75M |
| Average Diluted Shares Outstanding | 43.22M | 43.23M | 43.16M | 43.13M | 23.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |